Autosomal recessive nonsyndromic deafness 13 is a genetic cause of hearing loss without other medical problems. People with this condition usually have sensorineural hearing loss that can be present at birth or start in early childhood. Not everyone will have the same experience, and hearing levels can range from mild to profound in one or both ears. The condition is lifelong, but hearing aids or cochlear implants and early speech and language support can help daily communication. It does not affect life expectancy, and genetic counseling can guide family planning.
Overview
Autosomal recessive nonsyndromic deafness 13Symptoms
Autosomal recessive nonsyndromic deafness 13 causes bilateral sensorineural hearing loss, usually severe and noticed at birth or in early infancy. Babies may miss newborn hearing screens, not startle to sound, and later show delayed speech. No other medical features occur.
Outlook and prognosis
Most people with Autosomal recessive nonsyndromic deafness 13 have stable, early-onset hearing loss that doesn’t affect other body systems. With timely newborn screening, hearing technology, and language support, children can develop speech, learning, and social skills well. Lifelong hearing care helps adapt to needs over time.
Causes and risk factors
Autosomal recessive nonsyndromic deafness 13 stems from inheriting two faulty copies of a hearing gene. Risk increases with parental carrier status, family history, or consanguinity. Noise, ototoxic drugs, and infections don’t cause it but may worsen hearing.
Genetic influences
Genetics are central in Autosomal recessive nonsyndromic deafness 13: two nonworking gene copies cause the condition. Variants in the DFNB13-related gene disrupt inner-ear function, leading to hearing loss without other features. Carrier parents have a 25% chance per pregnancy.
Diagnosis
Diagnosis of Autosomal recessive nonsyndromic deafness 13 starts with hearing tests and family history. Genetic tests (hearing-loss panels) confirm the cause; this is the genetic diagnosis of Autosomal recessive nonsyndromic deafness 13. Inner-ear imaging may assist in selected cases.
Treatment and drugs
Treatment for Autosomal recessive nonsyndromic deafness 13 focuses on hearing support and communication. Options often include hearing aids, cochlear implants when appropriate, and early speech–language therapy, plus sign language or cued speech. Regular audiology follow-up and genetic counseling help guide long‑term care.
Symptoms
Many early features of Autosomal recessive nonsyndromic deafness 13 relate to how a baby or child responds to sound in everyday settings. Parents may notice missed reactions to soft voices, delayed babbling, or difficulty following speech in noisy rooms. The changes are often subtle at first, blending into daily life until they become more noticeable. These features center on hearing only—growth, vision, and appearance are otherwise typical.
A baby may miss soft voices or toys that rattle quietly. Loud claps or alarms still startle, but everyday sounds may go unnoticed.
Newborn hearing screening may flag a concern at birth or soon after. Follow-up tests help confirm the type and degree of hearing loss.
In Autosomal recessive nonsyndromic deafness 13, hearing is affected in both ears, often to a similar degree. Tests usually show sensorineural loss tied to the inner ear or hearing nerve.
Babbling may be quieter or less varied, and first words can come later than expected. Without reliable access to sound, speech clarity may lag until supports are in place.
How people usually first notice Autosomal recessive nonsyndromic deafness 13?
Many families first notice something is different when a baby with autosomal recessive nonsyndromic deafness 13 doesn’t startle at loud sounds or doesn’t turn toward a parent’s voice the way most infants do. Newborn hearing screening, which is routine in many countries shortly after birth, often flags reduced or absent hearing responses and prompts a follow-up test. For many, these first signs of autosomal recessive nonsyndromic deafness 13 lead to early audiology evaluation and genetic testing, even when the child looks healthy and has no other medical features.
Types of Autosomal recessive nonsyndromic deafness 13
Autosomal recessive nonsyndromic deafness 13 is a genetic/congenital condition with recognized clinical variants defined by the specific gene changes. These variants mainly differ in when hearing loss starts, how quickly it progresses, and how well hearing devices help. Symptoms don’t always look the same for everyone. When people search for types of Autosomal recessive nonsyndromic deafness 13, they usually mean these clinical variants that shape age of onset and severity.
Congenital severe-profound
Hearing loss is present from birth and is typically severe to profound. Many notice little to no response to everyday sounds, and hearing aids may offer limited benefit.
Early childhood progressive
Hearing starts near normal or mild in infancy but worsens during early childhood. Families may see frequent volume increases on devices or speech becoming less clear over time.
Adolescent-onset
Hearing is near typical in early childhood, with decline beginning in the pre-teen or teen years. School settings may reveal new difficulty following speech in noise or from a distance.
Residual low-frequency
Low-pitched sounds are reduced while high-pitched sounds are relatively better preserved. People may hear beeps or birds well but miss deeper voices or background hums.
Good device response
Many benefit from appropriately fitted hearing aids or, if needed, cochlear implants. Speech understanding can improve notably with consistent use and therapy.
What genetics can tell you about symptoms
Some people with autosomal recessive nonsyndromic deafness 13 have changes in the DFNB13/PCDH15 gene that disrupt inner‑ear hair cell links, leading to congenital, sensorineural hearing loss in both ears. Different variants can change severity, from moderate loss to profound deafness.
Causes and risk factors
The main cause is inheriting two copies of a gene change that disrupts inner ear function.
It follows an autosomal recessive pattern, so each parent is usually a healthy carrier.
Key risk factors for autosomal recessive nonsyndromic deafness 13 include a family history of early hearing loss and parents who are related by blood.
Loud noise, certain medicines that can harm the inner ear like some antibiotics, or severe ear infections do not cause it but can worsen hearing over time.
Doctors distinguish between risk factors you can change and those you can’t.
Environmental and biological risk factors
Autosomal recessive nonsyndromic deafness 13 begins in early development, so most risk is set before birth. While early symptoms of Autosomal recessive nonsyndromic deafness 13 are often noticed in infancy, the chance of it occurring is shaped mainly by internal biology, with a smaller contribution from certain exposures around conception. Some biological risks are written in our genes, others arise through environment. Below are biological and environmental elements that may nudge risk, though for this condition their influence is generally small.
As sperm-producing cells divide over many years, new gene changes become more likely. For this condition, having new changes on both copies is uncommon, so any added risk is likely small.
Ionizing radiation to the testes or ovaries can increase DNA damage in sperm or eggs. This could slightly raise the chance of a new gene change relevant to this condition, though direct links are rare.
Certain chemotherapies and pelvic, testicular, or ovarian radiation can harm sperm or eggs. A temporary waiting period before trying to conceive is often advised to lower the chance of passing along new gene changes.
High-level exposure to some solvents, pesticides, or heavy metals has been linked with increased DNA damage in sperm or eggs. Evidence tying these exposures to this specific diagnosis is limited, so any effect on risk is probably small.
Genetic risk factors
Autosomal recessive nonsyndromic deafness 13 happens when both copies of a single hearing gene carry harmful changes passed down in a family. Some risk factors are inherited through our genes. Because early symptoms of Autosomal recessive nonsyndromic deafness 13 can be subtle in milder cases, families with a history often consider carrier testing or targeted genetic testing. Patterns can vary between families and populations because different changes in the same gene can affect how the gene works.
Recessive inheritance: Two nonworking copies of the DFNB13‑linked hearing gene are needed for the condition to appear. One altered copy alone usually does not cause hearing loss.
Carrier parents: When both parents silently carry one gene change, each pregnancy has a 25% chance of a child with the condition. There is also a 50% chance the child will be a carrier and a 25% chance of neither change.
Compound heterozygosity: Two different harmful changes in the same gene, one from each parent, can cause Autosomal recessive nonsyndromic deafness 13. This has the same effect as inheriting two identical changes.
Consanguineous parents: Parents who are related by blood have a higher chance of carrying the same rare variant. This increases the likelihood their children inherit two altered copies.
Founder variants: In some communities, a single historical gene change became common over generations. This raises carrier rates and the chance that two carriers will have an affected child.
Copy number changes: Large deletions or duplications that remove or disrupt parts of the DFNB13‑linked gene can cause the condition. These structural changes damage gene function much like smaller mutations.
Sibling recurrence: Once one child is diagnosed and both parents are carriers, full siblings have a 25% chance of also being affected. Unaffected siblings may still be carriers.
De novo risk: New changes arising in only one copy of the gene typically do not cause DFNB13. For a child to be affected, both copies must be altered, making purely de novo cases uncommon.
Variable expressivity: Different gene changes can lead to different degrees and timing of hearing loss in families with DFNB13. This helps explain why some relatives notice earlier or more severe changes than others.
Lifestyle risk factors
Autosomal recessive nonsyndromic deafness 13 is a genetic condition; lifestyle habits do not cause it, but they can influence symptom management, residual hearing, and outcomes with hearing technology. Practical daily choices can help protect any remaining hearing, reduce listening fatigue, and support communication. Below are lifestyle risk factors for Autosomal recessive nonsyndromic deafness 13 and how lifestyle affects Autosomal recessive nonsyndromic deafness 13 in day-to-day life.
Regular exposure to loud venues, power tools, or concerts can accelerate loss of any residual hearing and worsen tinnitus. Using earplugs and limiting duration helps preserve cochlear function and device benefit.
High-volume headphone use can further damage hair cells and reduce clarity even with hearing aids or implants. Follow the 60/60 rule (≤60% volume for ≤60 minutes at a time) to protect remaining hearing.
Frequent high-dose aspirin or NSAIDs can temporarily worsen hearing or tinnitus, complicating communication. Use the lowest effective dose and discuss safer alternatives with your clinician.
Nicotine and smoke reduce cochlear blood flow and can hasten decline in residual hearing. Quitting improves inner-ear perfusion and may support better outcomes after cochlear implant surgery.
Risk prevention
Autosomal recessive nonsyndromic deafness 13 is inherited, so you can’t prevent the condition itself, but you can lower the chance of complications and support hearing health early. Prevention is about lowering risk, not eliminating it completely. Many families focus on early detection, hearing protection, and informed family planning. A genetics professional can also help you understand risks for future pregnancies and discuss your options.
A genetics professional can explain how this condition is passed down and what it means for your family. They can outline recurrence risks and help you plan next steps.
If you’re planning a pregnancy, ask about carrier testing for you and your partner. Finding out carrier status can guide decisions and timing.
Some couples consider in‑vitro fertilization with embryo testing or using donor eggs or sperm. Prenatal diagnosis is another option for those who wish to know during pregnancy.
Make sure your baby gets the routine hospital hearing screen and follow-up testing if needed. Knowing early symptoms of autosomal recessive nonsyndromic deafness 13 helps you act quickly if hearing seems reduced.
Transmission
Autosomal recessive nonsyndromic deafness 13 is not contagious; it cannot be caught or spread between people. It is passed through families in an autosomal recessive pattern, meaning a child needs to inherit two nonworking copies of the gene—one from each parent—to have the condition. Parents who each carry one changed copy usually have typical hearing and, with each pregnancy, have a 25% (1 in 4) chance of a child with Autosomal recessive nonsyndromic deafness 13, a 50% (1 in 2) chance of a child who is a carrier, and a 25% (1 in 4) chance of a child with two working copies. New genetic changes can occur, but most cases result from two carrier parents. If you have questions about how Autosomal recessive nonsyndromic deafness 13 is inherited, a genetic counselor can help clarify your family’s risks.
When to test your genes
Consider genetic testing if you have early-onset hearing loss without other health issues, a family history of similar hearing loss, or relatives known to carry GJB2 variants linked to autosomal recessive nonsyndromic deafness 13. Testing helps confirm the cause, guide hearing care choices, and clarify reproductive risks. Prenatal or preconception carrier screening is also reasonable.
Diagnosis
For many families, the first clue is a newborn hearing screen that’s not passed, followed by more detailed hearing tests. In older children, you might notice that responses to sounds are delayed or speech is slower to develop, which prompts evaluation. Early and accurate diagnosis can help you plan ahead with confidence. Testing focuses on confirming sensorineural hearing loss, then using genetic tools to look for the specific cause.
Hospitals use quick checks like otoacoustic emissions and auditory brainstem response shortly after birth. If a baby does not pass, a repeat screen or full diagnostic testing is arranged.
Detailed tests such as diagnostic auditory brainstem response, otoacoustic emissions, and tympanometry confirm the type and degree of hearing loss. Results in Autosomal recessive nonsyndromic deafness 13 usually show sensorineural loss without signs of middle-ear fluid.
A clinician looks for features that would suggest a broader syndrome and reviews prenatal, birth, and health history. This helps confirm a nonsyndromic pattern and guides which tests come next. Family history is often a key part of the diagnostic conversation.
A multigene hearing-loss panel or exome sequencing can identify changes in both copies of a relevant gene. A confirmed result provides the genetic diagnosis of Autosomal recessive nonsyndromic deafness 13 and explains recurrence risk for future pregnancies.
Stages of Autosomal recessive nonsyndromic deafness 13
Autosomal recessive nonsyndromic deafness 13 does not have defined progression stages. For many, the hearing difference is present from birth or early infancy and stays fairly stable, so it’s described by hearing test results rather than a gradual, step-by-step decline; early symptoms of autosomal recessive nonsyndromic deafness 13 may include not responding to quiet sounds or delays in speech. Different tests may be suggested to help confirm the type and degree of hearing loss, such as newborn hearing screening, otoacoustic emissions, and auditory brainstem response. Ongoing care usually involves periodic hearing checks and, when appropriate, genetic testing to confirm the cause and guide family planning.
Outlook and prognosis
For many living with autosomal recessive nonsyndromic deafness 13 (DFNB13), the day-to-day picture centers on hearing differences rather than other health problems. Many people ask, “What does this mean for my future?”, and the short answer is that life expectancy is expected to be typical, because DFNB13 affects hearing without involving other organs or development in most cases. Severity can vary: some are born with profound hearing loss, while others have partial loss that may be stable or slowly change over time. Early symptoms of autosomal recessive nonsyndromic deafness 13 can be subtle in infants—like not startling to loud sounds—or more obvious if a newborn hearing screen flags concerns.
Prognosis refers to how a condition tends to change or stabilize over time. In DFNB13, the long-term outlook mainly depends on the degree of hearing loss and how quickly hearing support is started. Hearing aids, cochlear implants, and speech-language therapy can support communication, schooling, and work, and there is no known increase in mortality tied to DFNB13 itself. Even though it can feel overwhelming, many people build strong communication skills through spoken language, sign language, or both, and participate fully in school, jobs, and family life.
Looking at the long-term picture can be helpful. With ongoing care, many people maintain independence and good quality of life, and mental health is better when communication access is reliable at home, school, and work. If hearing changes over time, care plans can be adjusted—new device programming, therapy refreshers, or exploring an implant if needed. Talk with your doctor about what your personal outlook might look like, including monitoring schedules and which hearing supports fit your goals.
Long-term effects
For many, day-to-day life centers on clear, reliable ways to communicate at home, school, and work, rather than on medical complications. The long-term effects of Autosomal recessive nonsyndromic deafness 13 mostly relate to hearing and communication across the lifespan, with general health otherwise typical. Long-term effects vary widely, and people’s paths can range from stable hearing to slow changes over time. Thinking about the long-term effects helps families anticipate language, education, and social needs from childhood through adulthood.
Most people have stable, bilateral inner-ear hearing loss from early life. In some, hearing can slowly worsen over years. The degree of loss can range from moderate to profound.
Early hearing differences can delay first words and affect pronunciation. Language timing and clarity often reflect how much accessible language someone had in early childhood.
Thinking, memory, and problem-solving are typically on track. Reading and classroom participation often relate to language access and classroom acoustics.
Communication barriers can sometimes lead to isolation, listening fatigue, or misunderstandings. Many also find strong identity and community within Deaf and hard-of-hearing spaces.
How is it to live with Autosomal recessive nonsyndromic deafness 13?
Living with autosomal recessive nonsyndromic deafness 13 often means growing up with stable hearing loss from birth or early childhood, while overall health and development are otherwise typical. Daily life can be full and connected with the right supports—visual communication like sign language, hearing technology when helpful, captioning, and accessible classrooms and workplaces make a real difference. Families, friends, and coworkers may need to learn communication strategies—facing you when speaking, reducing background noise, using text or video relay—which often strengthens relationships through clearer, more intentional communication. Many find community within Deaf and hard-of-hearing spaces, where culture, identity, and shared experience offer support and pride.
Treatment and drugs
Treatment for Autosomal recessive nonsyndromic deafness 13 focuses on improving hearing and communication rather than “curing” the underlying genetic change. Many people with this condition benefit from well-fitted hearing aids, and those with more severe or profound hearing loss may be candidates for cochlear implants after a thorough hearing evaluation and imaging. Beyond devices, speech and language therapy, auditory training, and classroom or workplace supports (like captioning, FM/remote microphone systems, and room acoustics adjustments) can make day-to-day communication easier. You might picture this as a team effort between you and your doctor, including audiologists, speech-language therapists, and sometimes genetic counselors who can discuss family planning and what test results mean. Although living with Autosomal recessive nonsyndromic deafness 13 can feel overwhelming, many people manage their symptoms and live fulfilling lives.
Non-drug treatment
Autosomal recessive nonsyndromic deafness 13 is a genetic form of hearing loss that mainly affects how sound is sensed, so care focuses on communication and access to sound. Non-drug treatments often lay the foundation for daily communication and participation. Early symptoms of Autosomal recessive nonsyndromic deafness 13 may appear in infancy, so starting support early helps speech and learning. Options range from hearing devices to language, education, and family supports.
Coordinated services in infancy and childhood support hearing, language, and development. Quick referral after newborn screening helps families start proven supports.
Small devices amplify sound for mild to severe hearing loss. Careful fitting and regular adjustments help people with Autosomal recessive nonsyndromic deafness 13 get the most benefit.
For severe-to-profound loss when hearing aids don’t help. The device bypasses damaged inner-ear cells to stimulate the hearing nerve, paired with rehabilitation afterward. Evaluation by a cochlear implant team confirms candidacy.
Wireless mics send a speaker’s voice directly to hearing devices. They improve understanding in noisy rooms, classrooms, and meetings.
Your genes may have an impact on how drugs work for you
For many with autosomal recessive nonsyndromic deafness 13, genes can shape how the body processes certain medications, influencing dose needs, side effects, or benefits. Pharmacogenetic testing may guide safer choices, especially to avoid ototoxic drugs that can worsen hearing.
Pharmacological treatments
There are currently no approved medicines that restore hearing in Autosomal recessive nonsyndromic deafness 13 (DFNB13). Drugs that target symptoms directly are called symptomatic treatments. In practice, pharmacologic care focuses on short-term issues—such as sudden hearing changes, ear infections, or preparing for cochlear implantation—rather than the underlying gene change. Medicines also do not change early symptoms of Autosomal recessive nonsyndromic deafness 13, but they may support hearing health in specific situations.
Prednisone by mouth or intratympanic dexamethasone may be used if hearing drops suddenly. Benefit in genetic deafness is uncertain, but prompt treatment can help protect any remaining hearing.
Amoxicillin is commonly used for acute middle‑ear infection that can temporarily worsen hearing. Clearing the infection does not change Autosomal recessive nonsyndromic deafness 13 but can reduce muffled hearing.
PCV13 and PPSV23 vaccines lower the risk of meningitis around cochlear implantation. A single pre‑operative antibiotic dose such as cefazolin is often given to reduce surgical infection risk.
Medicines like gentamicin and cisplatin can damage inner‑ear hearing cells. Doctors try to avoid or adjust these when possible and may choose safer alternatives.
Genetic influences
In most families, this follows an autosomal recessive inheritance pattern: both parents quietly carry one changed copy of the same gene, and a child needs two changed copies to be affected. Autosomal recessive nonsyndromic deafness 13 typically affects hearing only, without other medical features, because the gene involved plays a role in how the inner ear works. A “carrier” means you hold the gene change but may not show symptoms. When both parents are carriers, each pregnancy has a 25% chance of a child being affected, a 50% chance the child will be a carrier, and a 25% chance of inheriting neither change. Severity and timing can vary, even between siblings; early symptoms of Autosomal recessive nonsyndromic deafness 13 may show up at birth or in early childhood as reduced responses to sound. Genetic counseling and testing can help confirm the specific gene change, clarify who in the family may be a carrier, and guide planning for current or future children.
Is Autosomal recessive nonsyndromic deafness 13 genetic?
Genetics are central in Autosomal recessive nonsyndromic deafness 13: two nonworking gene copies cause the condition. Variants in the DFNB13-related gene disrupt inner-ear function, leading to hearing loss without other features. Carrier parents have a 25% chance per pregnancy.
Pharmacogenetics—how genetics influence drug effects
For people with Autosomal recessive nonsyndromic deafness 13, medicines rarely reverse the hearing loss itself, but genetics can still shape which drugs are safest and how your care team plans treatments such as cochlear implantation. Genetic testing can sometimes identify how your body may react to certain antibiotics that can injure the inner ear, especially aminoglycosides, helping doctors choose safer options or add extra hearing checks. This matters because a well‑known change in mitochondrial DNA greatly increases the genetic risk of aminoglycoside-induced hearing loss, even at standard doses, and some centers screen for it before using these drugs. Chemotherapies like cisplatin and some diuretics can also affect hearing; while the evidence is still growing, certain gene patterns may raise risk, so clinicians may adjust drug choice, dose, or monitoring. If surgery is planned, general pharmacogenetic markers that influence pain medicines or anesthesia (for example, genes that change how codeine is processed) can guide safer prescribing and dosing. Even so, genes are only one piece of the picture; your team will also consider age, other medicines, and overall health to tailor care and reduce the chance of drug‑related hearing problems.
Interactions with other conditions
Day-to-day, people with Autosomal recessive nonsyndromic deafness 13 most often notice interactions when another ear issue is in the mix. This type of hearing loss typically stays limited to the inner ear and doesn’t directly cause problems in other parts of the body, but chronic ear infections, wax buildup, or seasonal allergies can add a temporary conductive hearing loss on top of the permanent one, making listening even harder. Noise exposure and certain medications that can harm hearing—like some chemotherapy drugs, aminoglycoside antibiotics, or high-dose loop diuretics—may further reduce hearing, so careful medication review matters. Speech and language progress can also be slower if learning differences or autism are present, because each condition places extra demands on communication; mental health strains such as anxiety may increase when listening effort is high in school or work. Ask if any medications for one condition might interfere with treatment for another. With coordinated care across audiology, ear–nose–throat, and speech therapy, many living with Autosomal recessive nonsyndromic deafness 13 do well, even when managing it alongside other conditions.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Families and communities once noticed patterns of children born with normal health otherwise, yet who did not respond to sound. In small towns and large cities alike, teachers seated these children up front, and relatives learned to face them when speaking. Over time, people saw that hearing differences often appeared in more than one sibling, while parents heard normally.
Throughout history, people have described profound, stable hearing loss that began in early childhood and did not come with other medical concerns. Early medical notes focused on how soon the hearing loss appeared and how it affected speech. As hearing tests became available in the 20th century, clinicians could chart which pitches were missing and confirm that many children had severe to profound, permanent hearing loss without balance problems or other features.
From early theories to modern research, the story of Autosomal recessive nonsyndromic deafness 13 moved from observation to careful classification. Specialists grouped conditions by whether hearing loss occurred alone or with other health findings, and by how it ran in families. When large family trees showed hearing loss in siblings with unaffected parents, researchers suspected a recessive inheritance pattern. This meant a child had to receive two nonworking copies of the same gene to have the condition.
In recent decades, knowledge has built on a long tradition of observation. Advances in genetics allowed scientists to link certain family patterns to specific regions of DNA, and later to name the exact genes involved. As labs matched test results with hearing profiles, they learned that autosomal recessive nonsyndromic deafness includes several subtypes, each tied to a different gene, with “DFNB13” marking one of these subtypes. Genetic testing then confirmed what families had long noticed—relatives without hearing loss often carried one nonworking copy silently.
Understandings have changed, but the day-to-day goal has stayed steady: identify children early and support communication. Newborn hearing screening programs, now routine in many countries, grew out of this historical path—from family stories, to audiology, to genetics. Today, the history of Autosomal recessive nonsyndromic deafness 13 reminds us why early symptoms of hearing loss matter and why shared information across generations helps guide timely care.